Heather Jacene, MD, PhD, will become chief of molecular imaging and theranostics at Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical Faculty Physicians (HMFP) Radiology, effective March 23, 2026.
Heather Jacene, MD, PhD
Jacene currently serves as clinical director of nuclear medicine at Dana-Farber Cancer Institute, and her appointment comes as part of a clinical collaboration among Dana-Farber, BIDMC, and HMFP, according to BIDMC. Dana-Farber is set to open a new cancer hospital in 2031.
Credited with harmonizing practice across hospitals, Jacene's accomplishments include initiating and creating the multidisciplinary theranostics service at Dana-Farber, the first to be designated as a Comprehensive Radiopharmaceutical Therapy Center of Excellence by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), BIDMC said.
In addition to her duties at BIDMC, Jacene is the current president of the SNMMI.
